logo-loader

Alliance Pharma appoints top Walgreens-Boots-Alliance manager as non-executive director

Published: 03:03 29 Jun 2021 EDT

Alliance Pharma PLC - Alliance Pharma appoints top Walgreens-Boots-Alliance manager as non-executive director

Alliance Pharma PLC (LON:APH) appointed Kristof Neirynck as an independent non-executive director.

He is currently group vice-president and chief marketing officer at retail pharmacy giant Walgreens-Boots-Alliance (WBA).

READ: Alliance Pharma chairman says integration of Biogix and Amberen is largely complete

The AIM-listed firm said he brings almost 20 years of international consumer brand experience including complex omni-channel business models, direct-to-consumer strategies and cross border e-commerce into China.

Neirynck started his career in 2002 at Procter & Gamble in Belgium before moving to Procter & Gamble International in Switzerland in 2004, where he worked for 11 years.

He joined WBA in 2015 as vice-president & global category director skin care before being appointed to his current role in 2017. He has global responsibility for the portfolio of more than 20 WBA-owned brands across beauty and consumer healthcare, representing more than US$4bn in sales.

He will join the healthcare group on 1 December, bringing back the number of independent non-executive directors to four after Nigel Clifford left on 30 April.

“Kristof brings outstanding operational and strategic experience of the consumer healthcare market, gained at global businesses,” David Cook, Alliance Pharma's chairman, said in a release.

“His international, omni-channel and marketing experience is highly complementary to the skillset of the existing board members as we focus on the group's international expansion."

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

17 minutes ago